RNAZ

$0.00

(

+0.00%

)
Quote details

stock

Transcode Therapeutics Inc

NASDAQ | RNAZ

10.17

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$8.27M

Market Cap

-

P/E Ratio

-61.43

EPS

$739.20

52 Week High

$6.15

52 Week Low

HEALTHCARE

Sector

RNAZ Chart

Recent Chart
Price Action

RNAZ Technicals

Tags:

RNAZ Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue $535K
Costof Goods And Services Sold $535K
Operating Income -$16M
Selling General And Administrative $6M
Research And Development $9.6M
Operating Expenses $16M
Investment Income Net -
Net Interest Income -$623K
Interest Income $684
Interest Expense $27K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $535K
Income Before Tax -$17M
Income Tax Expense -$17B
Interest And Debt Expense -
Net Income From Continuing Operations -$17M
Comprehensive Income Net Of Tax -
Ebit -$17M
Ebitda -$16M
Net Income -$17M

Revenue & Profitability

Earnings Performance

RNAZ Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $7.3M
Total Current Assets $7.1M
Cash And Cash Equivalents At Carrying Value $5.8M
Cash And Short Term Investments $5.8M
Inventory -
Current Net Receivables -
Total Non Current Assets $201K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.3M
Other Non Current Assets -
Total Liabilities $9.3M
Total Current Liabilities $2.8M
Current Accounts Payable $2.6M
Deferred Revenue -
Current Debt -
Short Term Debt $77K
Total Non Current Liabilities $6.5M
Capital Lease Obligations $38K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $38K
Other Current Liabilities $119K
Other Non Current Liabilities -
Total Shareholder Equity -$2M
Treasury Stock -
Retained Earnings -$63M
Common Stock $103
Common Stock Shares Outstanding $356K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$13M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $535K
Capital Expenditures $22K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$22K
Cashflow From Financing $16M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout $31M
Dividend Payout Common Stock $31M
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$17M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue $535K
Costof Goods And Services Sold $535K
Operating Income -$16M
Selling General And Administrative $6M
Research And Development $9.6M
Operating Expenses $16M
Investment Income Net -
Net Interest Income -$623K
Interest Income $684
Interest Expense $27K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $535K
Income Before Tax -$17M
Income Tax Expense -$17B
Interest And Debt Expense -
Net Income From Continuing Operations -$17M
Comprehensive Income Net Of Tax -
Ebit -$17M
Ebitda -$16M
Net Income -$17M

RNAZ News

RNAZ Profile

Transcode Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

TransCode Therapeutics, Inc. (RNAZ) is an innovative biopharmaceutical company focused on advancing the treatment of metastatic diseases through the development and commercialization of novel therapeutic agents. Headquartered in Boston, Massachusetts, TransCode is leveraging its proprietary technologies to address significant unmet medical needs in oncology, with an emphasis on enhancing the effectiveness of cancer treatments. The company's commitment to transforming cancer care positions it as a potentially key player in the evolving biopharmaceutical landscape.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NEHC
+33.33%
$1.84
NUAI
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BLMZ
+12.51%
$0.20
BTG
+1.44%
$4.92
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BBD
+0.91%
$3.30
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
IXHL
-0.01%
$0.59
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
CLSK
-5.32%
$13.68
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
SRM
+53.27%
$10.30
PFE
+0.67%
$23.76
ACHR
-0.53%
$9.27
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
AG
+4.02%
$12.14
HOOD
-0.70%
$121.78
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NEHC
+33.33%
$1.84
NUAI
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BLMZ
+12.51%
$0.20
BTG
+1.44%
$4.92
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BBD
+0.91%
$3.30
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
IXHL
-0.01%
$0.59
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
CLSK
-5.32%
$13.68
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
SRM
+53.27%
$10.30
PFE
+0.67%
$23.76
ACHR
-0.53%
$9.27
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
AG
+4.02%
$12.14
HOOD
-0.70%
$121.78
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.